Institutional members access full text with Ovid®

Exposure to HIV-1-encoded Toll-like receptor 8 ligands enhances monocyte response to microbial encoded Toll-like receptor 2/4 ligands

Mureith, Marianne Wa,b; Chang, J Judyb; Lifson, Jeffrey Dc; Ndung'u, Thumbia; Altfeld, Marcusa,b

doi: 10.1097/QAD.0b013e32833ad89a
Basic Science: Concise Communication

Background: Chronic HIV-1 infection is characterized by high levels of persistent immune activation. Both HIV-1-encoded Toll-like receptor 7/8 (TLR7/8) ligands and TLR ligands encoded by products of microbial translocation have been implicated in inducing and sustaining immune activation in infected individuals, but the consequences of simultaneous exposure to different TLR ligands are not well understood.

Objective: To examine the impact of preexposure of monocytes to HIV-1-encoded TLR8 ligands on their ability to respond to subsequent stimulation with microbial TLR2/4 ligands.

Method: Stable monocytic cell lines (THP-1-Blue-CD14 cells) or primary monocytes were stimulated with ligands for TLR2, TLR4, and TLR8, including chemically inactivated HIV-1, alone, or in sequential combinations. Responses by THP-1 cells to TLR stimulation were quantified using Quanti-Blue colometric assay, and TLR-induced tumor necrosis factor-α production of primary monocytes was quantified by intracellular cytokine staining using flow cytometry.

Results: The exposure of monocytes to HIV-1 or HIV-1-derived TLR8 ligands sensitized these cells for TLR4 stimulation, resulting in a significantly higher response to lipopolysaccharide compared to cells that were not prestimulated with TLR8 ligands or HIV-1.

Conclusion: TLR crosstalk can enhance the pro-inflammatory monocytes response to products of microbial translocation and might play an important role in the modulation of immune function in HIV-1 infection.

aHIV Pathogenesis Programme, Doris Duke Medical Research Institute and KwaZulu-Natal Research Institute for TB and HIV, Nelson R. Mandela Medical School, University of KwaZulu-Natal, Durban, South Africa

bRagon Institute of MGH, MIT and Harvard, Charlestown, Massachusetts, USA

cAIDS and Cancer Virus Program, Science Applications International Corporation-Frederick, National Cancer Institute, Frederick, Maryland, USA.

Received 28 August, 2009

Revised 1 April, 2010

Accepted 10 April, 2010

Correspondence to Marcus Altfeld, MD, PhD, Associate Professor, Harvard Medical School, Ragon Institute of MGH, MIT and Harvard, 149 13th Street, 6th floor, Charlestown, MA 02129, USA. E-mail: maltfeld@partners.org

© 2010 Lippincott Williams & Wilkins, Inc.